Francisco Schlottmann1, Marco G Patti1,2, Nicholas J Shaheen3. 1. Department of Surgery and Center for Esophageal Diseases and Swallowing, University of North Carolina, Chapel Hill, NC, USA. 2. Division of Gastroenterology and Hepatology, Department of Medicine, Center for Esophageal Diseases and Swallowing, University of North Carolina at Chapel Hill, CB#7080, Chapel Hill, NC, 27599-7080, USA. 3. Division of Gastroenterology and Hepatology, Department of Medicine, Center for Esophageal Diseases and Swallowing, University of North Carolina at Chapel Hill, CB#7080, Chapel Hill, NC, 27599-7080, USA. nshaheen@med.unc.edu.
Abstract
BACKGROUND: The emergence of novel endoscopic modalities has challenged the role of surgery for patients with Barrett's esophagus (BE) and high-grade dysplasia (HGD) or early esophageal adenocarcinoma. AIM: The aim of this study was to review the available evidence of the endoscopic treatment of HGD and early esopahgeal adenocarcinoma. RESULTS: For most patients with BE and HGD, endoscopic ablative therapy is the preferred treatment strategy. Patients with intramucosal adenocarcinoma (T1a) should be treated with endoscopic mucosal resection (EMR) followed by ablative therapy, in order to eradicate the remaining intestinal metaplasia. The best approach to treatment of adenocarcinoma with submucosal invasion (T1b) remains elusive. Endoscopic resection may be suitable for low-risk T1b tumors (well differentiated, without lymphovascular invasion and with superficial submucosal invasion); however, further data are necessary to better risk stratify this group. Careful endoscopic surveillance is recommended following complete eradication of intestinal metaplasia to detect recurrent disease. CONCLUSION: Patients with BE and HGD should undergo endoscopic ablative therapy. Patients with T1a adenocarcinoma should be treated with EMR and subsequent ablation of the entire BE segment. Low-risk T1b tumors may be suitable for endoscopic resection.
BACKGROUND: The emergence of novel endoscopic modalities has challenged the role of surgery for patients with Barrett's esophagus (BE) and high-grade dysplasia (HGD) or early esophageal adenocarcinoma. AIM: The aim of this study was to review the available evidence of the endoscopic treatment of HGD and early esopahgeal adenocarcinoma. RESULTS: For most patients with BE and HGD, endoscopic ablative therapy is the preferred treatment strategy. Patients with intramucosal adenocarcinoma (T1a) should be treated with endoscopic mucosal resection (EMR) followed by ablative therapy, in order to eradicate the remaining intestinal metaplasia. The best approach to treatment of adenocarcinoma with submucosal invasion (T1b) remains elusive. Endoscopic resection may be suitable for low-risk T1b tumors (well differentiated, without lymphovascular invasion and with superficial submucosal invasion); however, further data are necessary to better risk stratify this group. Careful endoscopic surveillance is recommended following complete eradication of intestinal metaplasia to detect recurrent disease. CONCLUSION:Patients with BE and HGD should undergo endoscopic ablative therapy. Patients with T1a adenocarcinoma should be treated with EMR and subsequent ablation of the entire BE segment. Low-risk T1b tumors may be suitable for endoscopic resection.
Authors: Roos E Pouw; Noor Heldoorn; Lorenza Alvarez Herrero; Fiebo J W ten Kate; Mike Visser; Olivier R Busch; Mark I van Berge Henegouwen; Kausilia K Krishnadath; Bas L Weusten; Paul Fockens; Jacques J Bergman Journal: Gastrointest Endosc Date: 2011-01-26 Impact factor: 9.427
Authors: K Nadine Phoa; Roos E Pouw; Frederike G I van Vilsteren; Carine M T Sondermeijer; Fiebo J W Ten Kate; Mike Visser; Sybren L Meijer; Mark I van Berge Henegouwen; Bas L A M Weusten; Erik J Schoon; Rosalie C Mallant-Hent; Jacques J G H M Bergman Journal: Gastroenterology Date: 2013-03-28 Impact factor: 22.682
Authors: Castigliano M Bhamidipati; George J Stukenborg; Christopher J Thomas; Christine L Lau; Benjamin D Kozower; David R Jones Journal: Ann Thorac Surg Date: 2012-05-22 Impact factor: 4.330
Authors: Nicholas J Shaheen; Bruce D Greenwald; Anne F Peery; John A Dumot; Norman S Nishioka; Herbert C Wolfsen; J Steven Burdick; Julian A Abrams; Kenneth K Wang; Damien Mallat; Mark H Johnston; Alvin M Zfass; Jenny O Smith; James S Barthel; Charles J Lightdale Journal: Gastrointest Endosc Date: 2010-04 Impact factor: 9.427
Authors: Jessica M Leers; Steven R DeMeester; Arzu Oezcelik; Nancy Klipfel; Shahin Ayazi; Emmanuele Abate; Jörg Zehetner; John C Lipham; Linda Chan; Jeffrey A Hagen; Tom R DeMeester Journal: Ann Surg Date: 2011-02 Impact factor: 12.969
Authors: Sarina Pasricha; William J Bulsiewicz; Kelly E Hathorn; Srinadh Komanduri; V Raman Muthusamy; Richard I Rothstein; Herbert C Wolfsen; Charles J Lightdale; Bergein F Overholt; Daniel S Camara; Evan S Dellon; William D Lyday; Atilla Ertan; Gary W Chmielewski; Nicholas J Shaheen Journal: Clin Gastroenterol Hepatol Date: 2014-05-09 Impact factor: 11.382
Authors: Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale Journal: N Engl J Med Date: 2009-05-28 Impact factor: 91.245